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3
THE ASSOCIATION BETWEEN ELEVATED HIPPOCAMPAL GLUTAMATE
LEVELS AND COGNITIVE DEFICITS IN EPILEPSY.
Michele S. Buragas. (Sponsored by Idil Cavus.) Departments of Neurosurgery and
Psychiatry, Yale University School of Medicine, New Haven, CT.
The purpose of this study was to investigate the association between extracellular
basal hippocampal glutamate levels and cognitive function in epileptic patients. We used
the zero-flow microdialysis method to measure the extracellular concentrations of
glutamate in the epileptogenic and non-epileptogenic hippocampus of 23 awake epileptic
patients during the interictal period. All patients underwent extensive
neuropsychological testing to assess cognitive functioning prior to probe implantation.
Basal glutamate levels in the epileptogenic hippocampus were significantly higher than
the non-epileptogenic hippocampus (mean, 11.96 micromolar (µM) versus 2.92 µM,
respectively). Elevated basal glutamate levels in the epileptogenic hippocampus
correlated with decreased scores on the Verbal Selective Reminding Test (V-SRT) (R2 =
0.36, p = 0.0244). When controlling for MRI-detected hippocampal atrophy within
epileptogenic regions, elevated basal glutamate levels within atrophic hippocampus
correlated with decreased cognitive functioning measured by both the V-SRT (R2 =
0.7764, p = 0.0204) and Performance Intelligence Quotient (PIQ) (R2 = 0.7324, p =
0.0297), but not within non-atrophic hippocampus (V-SRT: R2 = 0.1013, p = 0.4424;
PIQ: R2 = 0.2303, p = 0.2288). These data suggest that elevated basal glutamate levels in
the epileptogenic hippocampus may be implicated in the pathogenesis of hippocampal
atrophy and may contribute to impaired cognitive functioning involving verbal memory
and visual-spatial skills in patients with temporal lobe epilepsy.
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Introduction
Glutamate as a Principal Neurotransmitter and Excitotoxin
Glutamate is the principal excitatory neurotransmitter in the brain, and it is
thought to mediate learning and memory (1). Glutamate was first suggested to play a role
in central nervous system metabolism in 1943, when Price and colleagues (2) reported the
successful treatment of petit mal seizures with orally administrated glutamate. Although
this claim regarding the therapeutic effect of glutamate could not be substantiated by later
studies, the report sparked interest in glutamate’s involvement in brain function and
fostered an advent of research in this field (1). The excitatory effect of glutamate on the
central nervous system was first elucidated by Hayashi and colleagues (3), when the
application of glutamate to the cortex of dogs and humans led to “clonic convulsions.” A
plethora of physiologic and biochemical evidence has since implicated glutamate as a
fundamental excitatory neurotransmitter involved in clinically important neuroanatomical
networks, including the hippocampal pathways of learning and memory (4).
The extracellular concentration of glutamate in the healthy brain is normally kept
very low due to efficient glutamate re-uptake mechanisms. Meldrum and colleagues (5)
report that although glutamate is found in high intracellular concentrations throughout the
mammalian brain, the baseline level of extracellular glutamate approximates one
micromolar (µM). During neuronal transmission, glutamate is released into the synaptic
cleft and the concentration of the neurotransmitter rises transiently to approximately one
millimolar (mM) for the maximal activation of glutamate receptors. Efficient neuronal
and glial sodium-dependent excitatory amino acid transporters (EAATs) quickly remove
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glutamate from the synaptic cleft to return extracellular concentrations to normally low
baseline levels (6).
In pathological conditions, abnormal elevation in extracellular glutamate levels
may result in excitotoxic cell damage leading to neuronal cell death and impaired
function (7). In 1971, Olney and colleagues (8) introduced the term “excitotoxin” after
demonstrating that systemic administration of glutamate resulted in toxic damage to the
central nervous system, and that the excitatory properties of amino acids correlated
positively with their ability to produce neurotoxic damage. Both in vivo and in vitro
studies (7, 9, 10) demonstrated that excitotoxicity occurs following abnormally elevated
exposure to glutamate. The pathogenesis of glutamate-induced excitotoxic cell death
occurs via an acute sodium-dependent phase followed by a delayed calcium-dependent
phase (11). The acute component occurs within minutes of glutamate binding to the Nmethyl-D-aspartic acid (NMDA) receptor, during which the sodium influx is associated
with passive influx of water and chloride with resultant neuronal dendritic swelling. The
delayed component occurs hours post-exposure and is triggered by excessive calcium
influx, which produces a cascade-like effect leading to cell death (11, 12). This
excessive calcium influx has been implicated in the glutamate-induced injury of
hippocampal neurons (13). Moreover, Mattson and colleagues (14) report that the
hippocampal subpopulation of pyramidal cells in rats are particularly vulnerable to
glutamate-induced neurotoxicity when compared to bipolar or stellate cells, and
demonstrate that pyramidal cells in the CA1 hippocampal region show greatest
vulnerability to excitotoxic damage, followed by cells in the CA3 region, the CA2 region,
and finally the dentate gyrus.
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The Hippocampus and Memory
The hippocampus is a pivotal structure of the medial temporal lobe and its
functional integrity is requisite for learning and memory. Compelling evidence in
support of this comes from the famous case report of patient H.M. who underwent
bilateral hippocampectomy for treatment of medically refractory epilepsy, with resultant
post-surgical profound anterograde amnesia (15) despite preservation of intelligence.
While this memory impairment followed bilateral hippocampal loss, similar deficits have
been reported in patients undergoing unilateral hippocampal resection with prior
concomitant damage to the contralateral hippocampus, creating the functional equivalent
of bilateral hippocampal lesions (16). However, memory impairments are less severe in
patients undergoing unilateral hippocampectomy with intact contralateral temporal lobe
function (17). Furthermore, memory impairments following unilateral hippocampal
resection are dependent on surgical lateralization; verbal memory is more severely
impaired following resection of the dominant (usually left) hippocampus, while visualspatial learning deficits occur following non-dominant (usually right) hippocampectomy
(17). These lesion studies have generated a body of evidence suggesting that the
hippocampus is responsible for memory operations in the medial temporal lobe.
Although hippocampal participation in cognition is well recognized, the precise
role it plays in memory is still being elucidated. Memory is divided into two broad
classes; declarative (explicit) memory refers to the conscious recollection of facts and is
subdivided into semantic memory (one’s general knowledge base) and episodic memory
(one’s recollection of personal experiences), while non-declarative (implicit) memory
involves the non-conscious recollection of skills and comprises procedural learning,
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perceptual priming, and conditioning (18). Non-declarative memory functions
independently of the hippocampus, as Milner (19, 20) demonstrates that this form of
memory may be acquired, maintained, and retrieved even by patients who are profoundly
amnesic as a result of hippocampal damage. In contrast, declarative memory is critically
dependent on hippocampal function, although there is considerable debate regarding
whether the hippocampus serves as either the temporary storage site of semantic and
episodic information awaiting consolidation (21) or the permanent storage site of
episodic memory as multiple memory traces (22, 23). Moser and Moser (24) review
numerous studies investigating the use of spatial memory for navigation in both rodents
and humans, which collectively suggest the hippocampus is critically involved during the
encoding and retrieval of spatial memory. Moreover, isolated damage to the human
hippocampus has been reported to produce global deficits of declarative memory, with
greater disruptions in episodic memory than semantic memory (24). Finally, functional
imaging studies in healthy patients demonstrate hippocampal activation during encoding
of verbal and visual information (25). This growing body of evidence from imaging and
task-learning studies in both animal and human models clearly suggests that the
hippocampus is specifically involved in the encoding process of verbal and visual-spatial
memory.
Separate anatomical sub-regions of the hippocampus are differentially engaged in
the learning process, however the exact role these different segments play has not yet
been fully elucidated. Moser and Moser (24) suggest that the anterior one-third of the
hippocampus is functionally distinct from the posterior two-thirds. Based primarily on
animal studies, these investigators propose that episodic memory depends on the
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posterior two-thirds of the hippocampus alone, while the anterior hippocampus functions
in emotional control systems. In contrast, Ros and colleagues (26) demonstrate via
autoradiogram densitometry that the hippocampus is activated heterogeneously along its
anterior-posterior axis during spatial learning tasks in mice. The pattern of metabolic
activation reveals increased activity in the intermediate and posterior CA1 region during
early acquisition, and in the anterior and posterior CA1 region and the anterior dentate
gyrus during late acquisition (26). In a meta-analysis of positron emission tomography
(PET) imaging studies, Lepage and colleagues (27) report the anterior hippocampus is
engaged during the encoding of episodic memory while the posterior region becomes
activated during retrieval. Furthermore, human functional magnetic resonance imaging
(fMRI) studies demonstrate that processing novel information involves the anterior
hippocampus, while processing familiar material utilizes the posterior hippocampus (2830). Moreover, fMRI studies in primates suggest that the posterior hippocampus
mediates spatial information, in contrast to anterior regions which, in animals, appear to
direct non-spatial information processing (31). Similar fMRI studies in healthy humans
demonstrate significant activation of the posterior hippocampus during verbal learning as
compared to the anterior hippocampus (25, 32). Taken together, this evidence suggests
the anterior hippocampus is predominantly involved in the encoding process of novel
information, while the posterior hippocampus is responsible for retrieval, processing
familiar information, and the mediation of verbal and spatial information.
The cellular basis for the storage of information is thought to depend upon a form
of synaptic plasticity known as long-term potentiation (33). Long-term potentiation
(LTP) upholds that repeated neuronal stimulation leads to synaptic sensitization, such that
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a constant level of stimulus evokes an augmented post-synaptic response which may last
for days to weeks. This strengthening of the synaptic connection between neurons
promotes efficacy of information processing, which is appropriate for the acquisition and
storage of memory (34). The molecular mechanisms of LTP are currently being
elucidated; it remains controversial whether this synaptic strengthening is maintained by
an augmented release of neurotransmitter from the pre-synaptic cell, an increased number
of receptors in the post-synaptic cell, or a combination of both (35). Moreover, it is
debated whether these molecular mechanisms underlying LTP are the same as those
responsible for memory (36), however there is considerable evidence suggesting this is
the case. LTP has been described in various hippocampal pathways, including the
Schaffer collateral – CA1 synapse and the perforant path – dentate granule cell synapse
(18, 37). It is well documented that LTP is mediated by the interaction of glutamate with
its NMDA receptor (38). Beck and colleagues (37) report numerous studies
demonstrating that antagonists of NMDA receptors prevent induction of LTP and result
in spatial learning deficits in rodents. Furthermore, electrophysiological analysis of
hippocampal specimens from patients with temporal lobe epilepsy (TLE) has revealed
that activity-dependent synaptic plasticity for information storage similar to the rodent
model is also present within humans (37). These findings demonstrate that the excitatory
properties of glutamate within hippocampal pathways are crucial to learning and
memory.
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Impaired Cognition in Temporal Lobe Epilepsy
The hippocampal model of memory is exemplified by patients afflicted with
temporal lobe epilepsy (TLE), in which hippocampal pathology is associated with deficits
in learning in memory. The epileptogenic focus in this form of epilepsy involves the
medial temporal lobe, evidenced by studies demonstrating the localization of abnormal
electrical foci to this region, as well as data from postoperative pathology specimens
revealing histological abnormalities of the temporal lobe (39). TLE has long been
associated with cognitive deficits, particularly with impairments in intelligence quotient
(IQ) and verbal memory associated with long duration of epilepsy and frequent tonicclonic seizures (40). Multiple neuropsychological assessment tools have been used to
quantify cognitive function specifically related to learning and memory in these patients.
Briefly, the Wechsler Adult Intelligence Scale (WAIS) provides measures of general
intellectual functioning broadly categorized into Verbal Intelligence Quotient (VIQ) and
Performance Intelligence Quotient (PIQ); the Full Scale Intelligence Quotient (FSIQ) is a
composite of the VIQ and PIQ. The FSIQ is a broad-spectrum measure of cognition that
is mediated by global cortical processes; the VIQ and PIQ divide the FSIQ into verballymediated and nonverbally-mediated components, respectively. The Verbal Selective
Reminding Test (V-SRT) is designed to measure verbal learning and memory during a
multiple-trial list-learning task, which is mediated by dominant (usually left)
hippocampal function (41). An alternate format exists which measures spatial memory,
referred to as the Visual-Motor Selective Reminding Test (VM-SRT), and depends on
non-dominant (usually right) hippocampal function.
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Verbal memory impairments associated with TLE have been specifically
correlated to both pyramidal cell loss and MRI-detected hippocampal atrophy. First, Sass
and colleagues (42-46) examined the relationship between neuronal counts of pyramidal
cells in various hippocampal subfields and neuropsychological measures. They
demonstrated that neuronal loss in the CA3 and hilar regions is associated with verbal
memory impairment measured both by the verbal selective reminding test (V-SRT) (42)
and the intracarotid amobarbital procedure (IAP), in which one hippocampus is
anesthetized to permit independent testing of the contralateral temporal lobe (43).
Subsequent studies further elucidated that decreased pyramidal cell density correlates
with verbal memory impairment measured specifically by the V-SRT but not to overall
verbal intellectual functioning as measured by the VIQ (44), supporting the hypothesis
that memory impairment results from hippocampus-specific cell loss as opposed to global
dysfunction of the temporal neocortex. Furthermore, the extent of hippocampal cell loss
is correlated with the degree of verbal impairment in patients both without (45) and with
(46) structural lesions. Second, improvements in neuroimaging have permitted presurgical detection of mesial temporal sclerosis (MTS), which is the most common
pathological finding of TLE. MTS is characterized by severe neuronal loss and gliosis,
and its signature on MRI includes atrophy of the hippocampus on T1-weighted images
and increased signal intensity on T2-weighted images (47). This MRI-detected
hippocampal pathology in TLE patients has been associated with verbal memory
impairment. Westerveld (47) reports the correlation between hippocampal volume loss
and asymmetry of memory scores during the intracarotid amobarbital procedure (IAP);
the difference in performance between right and left hemispheres indicates impaired
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functioning of one hippocampus with preservation of contralateral performance.
Moreover, hippocampal volume loss correlates with deficits in baseline
neuropsychological functioning, particularly of verbal learning and recall. Lencz and
colleagues (48) report that among TLE patients with left-sided seizure foci, MRIdetermined left hippocampal volume correlates with Wechsler logical memory percent
retention scores, and left temporal lobe measurements correlate with performance on the
V-SRT. Kilpatrick and colleagues (49) report a strong association between the degree of
MRI-detected left hippocampal atrophy and severity of verbal memory and verbal
memory retention deficits measured by the Rey auditory verbal learning task. Taken
together, these data correlating both decreased pyramidal cell density and hippocampal
atrophy with impaired verbal memory in temporal lobe epilepsy patients clearly
demonstrate the necessity of cellular and macroscopic hippocampal integrity for proper
cognitive function.

Patients with Temporal Lobe Epilepsy
Epilepsy is a common disorder affecting approximately 15 per 1000 people (50)
with resultant significant morbidity and mortality. Mesial temporal lobe epilepsy
(MTLE) is the most common form of human epilepsy (51), and its underlying pathology
is most often mesial temporal sclerosis (MTS), hallmarked by hippocampal neuronal loss
and gliosis (52). MTLE is resistant to antiepileptic medications in approximately 75% of
cases (52). Significant disability has been reported in such patients, including depression
in approximately 50% of cases with suicidal ideation approaching 20%, and psychosis
occurring 6- to 12-fold more frequently than healthy counterparts (53). Further morbidity
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and mortality results from seizure injury (including fractures, burns, and death from
drowning and driving), in addition to death from status epilepticus, suicide, and sudden
unexplained death in epilepsy patients (SUDEP) (53). Moreover, the duration and
severity of epilepsy are associated with cognitive dysfunction, including significant
verbal memory decline (40, 54) and impairments of global intelligence measured by the
WAIS-R (40, 55), which contribute to decreased quality of life in these patients.
However, MTLE is surgically remediable by anteromesial temporal resection in 70 to
90% of patients (51, 52, 56). A landmark randomized controlled trial of temporal-lobe
surgery for medically refractory TLE demonstrated that 58% of the surgical group was
seizure free at one year postoperatively as compared to 8% in the medical group, with
improvements in quality of life reported for seizure-free patients (57). Although the cost
incurred through preoperative evaluation and surgical resection approximates $100,000
(56), it is comparable to the expense of antiepileptic drug therapy, medical intervention
for illness secondary to treatment failure, laboratory studies, office visits, and lost income
from unemployment. Furthermore, surgical resection in the treatment of medically
refractory epilepsy may improve quality of life and permit the patient to become a
functional member of society.

Microdialysis Measurements of the Glutamate Levels in the Epileptogenic Hippocampus
The technique of microdialysis has been applied to patients with refractory
medical temporal lobe epilepsy undergoing intracranial depth electrode monitoring to
identify seizure focus for possible resection. In this technique, microdialysis catheters are
implanted into the brain region of interest so that extracellular brain fluid may be sampled
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and analyzed for composition and concentrations of neurotransmitters (58, 59). Chemical
substrates within the brain’s interstitial fluid diffuse down a concentration gradient across
a semi-permeable dialysis membrane into the perfusion fluid inside the catheter. The
perfusion fluid is then collected and analyzed (58, 59).
Microdialysis techniques have been employed to study animal models of epilepsy,
revealing an association between seizure activity and elevated glutamate levels (60-63).
Ueda and colleagues (60) demonstrated an increase in extracellular hippocampal
glutamate concentrations during the interictal period of freely-moving rats with chronic
kainic-acid induced seizures. Engstrom and colleagues (61) found spontaneous interictal
glutamate elevations up to 8 times the basal level in 80% of rats with iron-induced
chronic focal epilepsy. Smolders and colleagues (62) report that during pilocarpineinduced limbic convulsions in the freely moving rat, glutamate levels are significantly
increased in the hippocampus.
Similarly, several human microdialysis studies report that glutamate levels in the
hippocampus of TLE patients may be elevated to neurotoxic ranges (64-70). Early
intracerebral microdialysis studies revealed a dramatic increase of extracellular glutamate
during the onset and occurrence of seizures (64, 65). Wilson and colleagues (66) report
that the glutamate increase during seizures in the human hippocampus is similar to the
glutamate rise seen in the chronic kainate rat model of epilepsy. In patients undergoing
anteromesial temporal resection, microdialysis recovery of glutamate from spontaneously
epileptiform hippocampus was significantly greater than glutamate recovery from nonepileptiform hippocampus (67, 68). A recent microdialysis study by Cavus and
colleagues (69) comparing epileptogenic and non-epileptogenic hippocampus during
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interictal periods demonstrates that while glutamate levels remain low in nonepileptogenic regions, basal extracellular glutamate levels are elevated to potentially
neurotoxic ranges in the epileptogenic hippocampus. Moreover, During and Spencer (70)
report that extracellular glutamate levels in the epileptogenic hippocampus rise further
above baseline immediately preceding seizures and remain elevated for prolonged postictal periods as compared to healthy brain, possibly exacerbating neurotoxic damage.
Furthermore, extracellular glutamate concentrations have been found to increase
significantly during the performance of complex figure memory tasks, and this elevation
is both augmented and prolonged in epileptogenic hippocampus, suggesting that the
epileptic brain is particularly vulnerable to the cognitive activation-induced glutamate
release (71). Recent evidence from microdialysis studies has further demonstrated that
elevated basal glutamate levels in the epileptogenic hippocampus are correlated with both
decreased neuronal density measured by histological analysis and MRI-detected
quantitative hippocampal atrophy (Cavus, unpublished data), suggesting that glutamate
elevation to neurotoxic levels may mediate the neuronal cell loss and sclerosis associated
with cognitive deficits.
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Statement of Purpose
The purpose of this study is to identify the relationship between basal
hippocampal glutamate levels and cognitive function in patients with TLE. In brief
review, glutamate is the principal excitatory neurotransmitter and levels remain low in
healthy brain, however concentrations may rise to neurotoxic levels in the epileptogenic
hippocampus (1, 5, 7, 64-70). The hippocampus is responsible for learning and memory
(15-17, 24-27), thus impaired hippocampal function in TLE is associated with cognitive
deficits (40, 54, 55). Specifically, microdialysis evidence demonstrates that elevated
glutamate levels are associated with cell loss and hippocampal atrophy (Cavus,
unpublished data), and previous studies have demonstrated that both cell loss and
hippocampal atrophy are associated with verbal memory impairment (42-49). We
therefore hypothesize that elevated basal glutamate levels in the epileptogenic (and often
atrophic) hippocampus will be associated with poorer cognitive function. Further, we
hypothesize that elevated basal glutamate levels in the epileptogenic hippocampus are
associated particularly with impaired verbal memory measured by a neuropsychological
test specific for hippocampal verbal functioning, the verbal selective reminding task, but
not with global intelligence measured by the Verbal IQ, Performance IQ, and Full Scale
IQ, as these tests are more dependent upon cortical processes and less dependent on
memory and hippocampal-specific processes. Conversely, we hypothesize that the low
basal glutamate level in healthy non-epileptogenic hippocampus will not be associated
with verbal memory deficits.
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Methods
Patients
Patients with drug-resistant epilepsy receive a phased evaluation of their illness to
localize their seizure focus for possible surgical resection. All patients undergo Phase I
clinical evaluation, in which they are admitted to an epilepsy unit for continuous audiovideo/electroencephalogram (EEG) monitoring with interictal and ictal scalp recording
during at least three typical seizures. Patients also receive brain magnetic resonance
imaging (MRI) with measurement of hippocampal volume, interictal and ictal singlephoton emission computed tomography (SPECT), interictal positron emission
tomography (PET), and extensive neuropsychological assessment. Phase II evaluation
consists of the intracarotid amobarbital procedure to determine lateralized memory
function and hemispheric dominance for language. Those patients in whom the seizure
focus could either not be localized by Phase I and II evaluations or if there was discordant
data were offered intracranial EEG monitoring (Phase III study), which involved
continuous audiovisual monitoring and EEG recording from a combination of depth,
subdural strip, and grid electrodes implanted intracranially in brain regions suspected of
being involved in seizure generation. These patients undergoing Phase III evaluation
were also invited to participate in the microdialysis study between 2000 and 2005.
Patients who consented to the study received implantation of depth electrodes which were
coupled to microdialysis probes, allowing for simultaneous electrophysiological
recording and sampling of the extracellular fluid. The recordings from the two depth
electrode contacts flanking the microdialysis membrane were used to determine whether
the microdialysis catheter was within or outside an epileptogenic area. The epileptogenic
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area was defined as the site of seizure origin in at least one seizure, whereas the nonepileptogenic sites were either not involved or were only secondarily involved
(propagated) during seizures. Epileptogenic probes are defined as microdialysis catheters
coupled to electrodes which recorded from epileptogenic areas, while non-epileptogenic
probes are those catheters which recorded from non-epileptogenic brain areas.
Twenty-two patients participated in the study. The mean age at the time of the
Phase III study was 36.3 years (standard deviation (SD), 12.4 years), with 13 female
patients: (mean age ± SD) 36.4 ± 12.1 years and 9 male patients: 36.2 ± 13.7 years. The
mean duration of epilepsy was 19.7 years (SD, 12.8 years), with the mean duration of
epilepsy for females equal to 18.1 ± 12.9 years and the mean duration for males equal to
22.1 ± 13.1 years (Table 1).
The sample was confined to English-speaking patients without co-morbid medical
conditions, 17 years or older, with a Wechsler Adult Intelligence Scale-Revised (WAISR) full scale IQ of 70 or greater, and the intracarotid amobarbital procedure
demonstrating left hemisphere speech dominance. For patients with multiple intracranial
microdialysis catheters, only data from probes located in the anterior hippocampus were
included in the study, based on previous reports of differential involvement of the
anterior and posterior hippocampus in cognitive processing (24, 26-32). Furthermore,
patients were excluded from the study if there was ambiguous probe placement (e.g. at
the juncture of white and grey matter), tumor, or diffuse dysplasia at or close to the
microdialysis catheters. All patients gave informed consent to the research protocol that
was approved by Yale University School of Medicine Human Investigation Committee.
Demographic data of participating patients was obtained by this investigator through
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medical chart review, and then recorded in a common database. Table 1 summarizes
patient information regarding gender, age of seizure onset and duration of epilepsy, probe
location, and classification of disease state as epileptogenic versus non-epileptogenic.
MRI findings of the hippocampus ipsilateral to the probe are reported, as well as
pathology at the probe site following resection if available.

Table 1. Patient Data
Case
No.

Sex

Age
(yr)

Epilepsy
Duration
(yr)
34.0

Probe
Location
(no. of
probes)
L hipp

1

M

53

2

M

3

Epileptogenic vs.
Non-Epileptogenic

Clinical
MRI
Findings

Pathology at
Probe Site

Epileptogenic

Atrophy

No surgery

39

12.6

L hipp

Epileptogenic

Atrophy

No surgery

M

40

40.3

L hipp

Epileptogenic

Atrophy

No surgery

4

M

17

5.2

R hipp

Epileptogenic

Atrophy

5

F

52

17.4

R hipp

Epileptogenic

Atrophy

6

F

32

28.3

R hipp

Epileptogenic

Atrophy

7

M

50

40.0

L hipp

Epileptogenic

No Atrophy

Hipp
Sclerosis
Hipp
Sclerosis
Hipp
Sclerosis
No surgery

8

F

38

2.0

L hipp

Epileptogenic

No Atrophy

No surgery

9

F

36

33.6

L hipp

Epileptogenic

No Atrophy

No surgery

10

F

49

47.8

L hipp

Epileptogenic

No Atrophy

No cell loss

11

F

46

9.1

L hipp

Epileptogenic

No Atrophy

12

M

23

23.2

R hipp

Epileptogenic

No Atrophy

Mild WM
gliosis
No cell loss

13

F

17

8.0

R hipp

Epileptogenic

No Atrophy

No surgery

14

F

52

8.3

M

27

11.0

Epileptogenic (1)
Non-Epileptogenic (1)
Non-Epileptogenic

No Atrophy
(2)
Atrophy

No surgery

15

L&R
hipp (2)
L hipp

No surgery

16

F

27

17.5

L hipp

Non-Epileptogenic

No Atrophy

No surgery

17

M

52

17.4

L hipp

Non-Epileptogenic

No Atrophy

No surgery

18

M

25

15.0

L hipp

Non-Epileptogenic

No Atrophy

No surgery

19

F

19

7.1

L hipp

Non-Epileptogenic

No Atrophy

No surgery

20

F

23

12.0

R hipp

Non-Epileptogenic

No Atrophy

No surgery

21

F

39

26.0

R hipp

Non-Epileptogenic

No Atrophy

No surgery

22

F

43

18.0

R hipp

Non-Epileptogenic

No Atrophy

No surgery

MRI = magnetic resonance imaging; M = male; F = female; L = left; R = right; hipp =
hippocampus; WM = white matter.
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Neuropsychological Assessment Techniques
Examiners in the Yale University School of Medicine Department of
Neuropsychology administered both the WAIS-R to measure Intelligent Quotients
(Verbal IQ, Performance IQ, and Full Scale IQ) and the Selective Reminding Tests
(Verbal SRT and Visuo-Motor SRT) during the pre-surgical screening of all patients.
Patients were treated with therapeutic ranges of anticonvulsant medication and
maintained seizure-free during the 12-hour period prior to examination.
Neuropsychological test results were obtained by this investigator through a review of
patient charts and subsequently compiled into a common database.
The WAIS-R (72) is a core measure of global intellectual functioning in which an
examiner asks tests questions and displays puzzles. The patient’s responses are recorded
in an individual response booklet and scored. The WAIS consists of 6 verbal subtests
(Information, Digit Span, Vocabulary, Arithmetic, Comprehension, and Similarities) in
addition to 5 performance subtests (Picture Completion, Picture Arrangement, Block
Design, Object Assembly, and Digit Substitution). Sub-scores on the Verbal Intelligence
Quotient (VIQ) subtests and Performance Intelligence Quotient (PIQ) are combined to
determine a composite Full Scale Intelligence Quotient (FSIQ) (41).
The Verbal Selective Reminding Test (V-SRT) (73) consists of a list of 12
unrelated words which are presented to the subject and must be recalled over multiple
trials immediately following recitation. The examiner will repeat only those words not
recalled by the subject on the previous trial, permitting the assessment of both short-term
and long-term memory. Stimulus exposure continues until the patient recalls the entire
list on two consecutive trials, or a total of 12 trials have been performed (41). Standard
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scoring yields measures of total recall, long-term memory storage, long-term memory
retrieval, consistent long-term memory retrieval, and short-term memory retrieval, which
are highly correlated (42). Factor analysis by Westerveld and colleagues (74) has
demonstrated that these measures constitute a single factor. V-SRT scores are therefore
reported as a single factor using a z-score distribution (average = 0, standard deviation =
1), in which a score of 0.0 equals the average of non-epileptic samples studied by
Westerveld. Negative scores indicate performance below average, while positive scores
are above average (45). The Visual-Motor Selective Reminding Test (VM-SRT) is
administered and scored in a similar fashion to the V-SRT, with visual stimuli replacing
the list of 12 words and recall assessed through the drawing of stimuli after exposure.

Microdialysis Procedure
Microdialysis probes coupled to depth electrodes (Spencer probe; Ad-Tech
Instrument, Racine, WI) were implanted stereotaxically in hippocampal regions
suspected of seizure involvement. All surgeries were performed by Drs. Dennis Spencer,
Kenneth Vives, and members of the Yale-New Haven Hospital Department of
Neurosurgery. The design of the earlier Spencer probe has been modified (75). Briefly,
the probes are CMA custom-modified microdialysis probes (CMA/20 concentric flexible
probe, 20 kDA membrane pore size, CMA, North Chelmsford, MA) which allow stable
flow, recovery, and dialysate collection throughout the duration of intracranial EEG
monitoring. The dialysis probe is inserted into a polyurethane/silastic flexible depthelectrode (1 mm i.d., Ad-Tech Instrument Co., Racine, WI), which has perforations
between contacts 1 and 2 to allow for fluid exchange with the membrane. The total
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diameter of this combination microdialysis/depth electrode (Spencer probe) is 1.85 mm.
The probes were sterilized by gamma radiation and flushed with sterile artificial
extracellular fluid (AECF) to ensure patency prior to insertion. After surgery, MRI was
used to verify the location of the probes and distinguish between anterior and posterior
hippocampal placement. (See Fig 1, A-C.)

Fig 1, A-C. Microdialysis catheters prior to, during, and post-surgical implantation.
(A) Subdural grid electrode and Spencer depth electrode with microdialysis catheter
prior to intracranial implantation. (B) Intraoperative implantation of depth electrodes
with attached microdialysis catheters and placement of subdural grid electrodes into the
temporal cortex of a patient undergoing Phase III evaluation. (C) Magnetic resonance
image from a patient with one Spencer probe in the right hippocampus, highlighted in
red. Depth electrode contacts 1 through 8 are visible. The platinum contacts of the
depth electrode generate significant artifact and appear much larger than their actual
diameter of 1mm. The microdialysis membrane, which is not visible on magnetic
resonance imaging, lies between depth electrode contacts 1 and 2.

A
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Zero-Flow Study
The zero-flow microdialysis method provides an estimate of the true baseline
substrate concentration in the extracellular fluid under steady-state conditions (76, 77).
The study was conducted 2 to 5 days after surgical probe implantation, at least 6 hours
from any intracranially recorded seizure activity and at least 2 hours post-prandially, with
the patient quietly resting in the evening, to avoid the effects of acute probe implantation,
anesthesia, ictal activity, behavioral stimuli, or food intake (78-80). Patients were
maintained on their anti-epileptic medications for the duration of the study. Sterile
artificial cerebrospinal fluid (ACSF) (composition: 135mM NaCl, 3mM KCl, 1mM
MgSO4*7H2O, 1.2mM CaCl2*2H2O in 1mM sodium phosphate buffer at pH 7.4; YaleNew Haven Hospital Pharmacy) was infused into the hippocampus of awake patients via
the inlet tubing on the microdialysis probe using portable CMA107 syringe pumps
(CMA, North Chelmsford, MA). Chemical substrates in the hippocampal interstitial fluid
diffuse across the dialysis membrane into the artificial CSF within the probe, which is
then collected via the outlet tubing on the microdialysis probe into microvials. A flow
rate of 2.0 µl/min was initially infused over one hour to reach a steady state, at which
point two consecutive 20 µl dialysate samples were collected. The flow rate was then
gradually decreased to 1.0, 0.5, and 0.2 µl/min, allowing a period of 60 to 90 minutes
after each change in flow rate for equilibration; two consecutive 20 µl dialysate samples
were collected at each flow rate. The study was completed over 6 hours, and samples
were stored initially over dry ice then placed in a -80ºC freezer for later analysis of
neurometabolite concentration using high-performance liquid chromatography. Basal
levels of glutamate were determined using regression analysis with fit to second
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polynomial order to a flow of zero, which corresponds to steady state. The zero-flow
studies were performed by this investigator in conjunction with M. Cassaday, D. Ocame,
and S. Forselius.

High Performance Liquid Chromatography Analysis of Glutamate Levels
Glutamate levels were analyzed using high-performance liquid chromatography
(HPLC) modified from the method described by Bourdelais and Lakivas (81). Briefly, 1
µl of patient sample is added to 9 µl of an internal standard of alpha-aminoadipic acid
(AAA). This mixture is derivatized by adding 20 µl of an O-phthaldialdehyde. After
eight minutes, 20 µl of the derivatized sample is injected onto the column (3 um Phase II
ODS column, 3.2 x 100 mm cartridge, Bioanalytical Systems, Inc., West Lafayette, IN).
The mobile phase consists of 0.1M acetic acid (pH 6.0) with a 12 to 20% acetonitrile
gradient at a 1 ml/min flow rate. Within 30 minutes, chromatograms demonstrate
adequate separation showing glutamate approximately at 6.9 minutes and AAA at 7.7
minutes (see Fig 2). The excitation and emission wavelengths on the florescence detector
(Shimadzu Scientific Instruments, Columbia, MD) are set at 338nm and 425nm,
respectively. The sensitivity limit for glutamate is 0.1, based on a signal-to-noise ratio of
10:1. Peak areas of the neurometabolite on chromatograms are then compared with
external standards to determine the concentration in the samples using EZCHROME elite
software from ESA (Chelmsford, MA). HPLC analysis was kindly performed by M.
Cassaday and D. Ocame.
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Fig 2. High-performance liquid chromatogram
High-performance liquid chromatogram sample showing the peak separations for
aspartate (asp, 2.0µM), glutamate (glu, 1.7µM), the internal standard α-aminoadipic
acid (AAA), and glutamine (gln, 80.5µM). The standard curve graph for glutamine and
glutamate is shown in the inset. (Reprinted with permission from Cavus et al, Annal
Neurol 2005.)

Statistical Analysis
All statistical analyses were performed using JMP 5.0 Statistical Package (SAS
Institute Inc., NC). Data of neuropsychological results follow a normal distribution;
glutamate data were transformed by log for normalization. Data were analyzed by
analysis of variance (ANOVA) in which the neuropsychological variables (VIQ, PIQ,
FSIQ, V-SRT, and VM-SRT) were dependent measures in a two (disease state:
epileptogenic and non-epileptogenic) by two (laterality: right and left) analysis of
variance. Analysis of co-variance (ANCOVA) was employed for the analysis of disease
state (epileptogenic) controlling for clinical MRI findings (atrophy and non-atrophy).
Linear regression models were used to investigate relationships between glutamate and
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neuropsychological test performance based on a priori hypothesis. Significance level
was set at 0.05. Data are reported as mean ± standard error of the mean. This
investigator organized the dataset, and all statistical analyses were performed by I. Cavus,
M.D., R. Gueorguieva, and B. Roach in conjunction with this investigator.
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Results
Twenty-two patients were implanted with a total of 23 Spencer probes in the
anterior hippocampus. Based on the intracranial EEG evaluation of spontaneous
seizures, 14 hippocampal probes were classified as epileptogenic and 9 as nonepileptogenic. Of the 14 epileptogenic probes, 9 were located in the left hippocampus
and 5 in the right hippocampus; 6 were in atrophic hippocampus, and 8 in non-atrophic
hippocampus. Of the 9 non-epileptogenic probes, 5 were located in the left hippocampus
and 4 in the right hippocampus; only 1 was located in atrophic hippocampus while 8 were
in non-atrophic hippocampus (Table 1.)
The extracellular basal glutamate concentration from all microdialysis probes was
estimated using the zero flow method and found to be 8.42 ± 10.47µM (mean ± SD), n =
23. The extracellular basal glutamate concentration in the non-epileptogenic
hippocampus was 2.92 ± 1.37 µM (n = 9). In contrast, the basal glutamate concentration
in the epileptogenic hippocampus was significantly greater (11.96 ± 12.24 µM, n = 14, p
= 0.0199, t-test on log-transformed data) than in the non-epileptogenic hippocampus (see
Fig 3). These results are consistent with prior studies that have demonstrated the
epileptogenic hippocampus exhibits a higher basal level of glutamate compared to the
non-epileptogenic hippocampus (69, 70). Since glutamate levels in the epileptogenic and
non-epileptogenic hippocampus are significantly different, and our a priori hypothesis
predicts that the glutamate levels in the epileptogenic hippocampus may impair cognitive
performance, we examined the relationship between glutamate and the
neuropsychological tests in the epileptogenic and non-epileptogenic hippocampus
separately.
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Fig 3. Basal extracellular glutamate levels in the epileptogenic and nonepileptogenic hippocampus.
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Basal glutamate levels in the epileptogenic hippocampus are significantly higher than
basal glutamate levels in the non-epileptogenic hippocampus. (* p < 0.05)

There has been considerable evidence suggesting that right and left hippocampus
play different roles in cognitive functioning (17), therefore we have analyzed the effects
of laterality within the epileptogenic and non-epileptogenic hippocampus. Within the
epileptogenic probes, the basal glutamate level from the left hippocampus (12.06 ± 12.23
µM, mean ± SD, n = 9) did not differ significantly from the right hippocampus (11.78 ±
13.71 µM, n = 5), p > 0.05, t-test on log-transformed data). Similarly, no difference was
found between the non-epileptogenic probes in the left hemisphere (2.34 ± 1.47µM, n =
5) and right hemisphere (3.64 ± 0.92µM, n = 4, p > 0.05, t-test on log-transformed data).
(See Figure 4, A-B.)
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Fig 4, A-B. Basal extracellular glutamate levels in the left and right epileptogenic
and non-epileptogenic hippocampus.
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The basal extracellular glutamate levels are comparable (p > 0.05) within the (A)
epileptogenic hippocampus and (B) non-epileptogenic hippocampus.
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Further analysis was conducted to examine the effect of laterality on the
relationship between individual neuropsychological assessment scores (VIQ, PIQ, FSIQ,
V-SRT, and VM-SRT) and basal glutamate levels in the epileptogenic and nonepileptogenic probes, using a linear regression model. Within the epileptogenic probes,
there were no significant correlations between basal glutamate concentrations and all
neuropsychological measures for the right and the left hippocampus (p > 0.05 for all
comparisons.) Of note, some results (VIQ, PIQ, and FSIQ) for the right hemisphere were
bordering statistical significance (VIQ: n = 6, R2 = 0.6139, p = 0.0652; PIQ: n = 6, R2 =
0.6113, p = 0.0662; FSIQ: n = 6, R2 = 0.6581, p = 0.0501). This finding may be spurious
due to our small sample size, however the elucidation of laterality would benefit from
further investigation in larger studies. Within the non-epileptogenic probes, there were
no significant correlations between the basal glutamate levels and the neuropsychological
measures of VIQ, FSIQ, V-SRT, and VM-SRT for the right and the left hippocampus (p
> 0.05). However, only the extracellular levels in the left non-epileptogenic
hippocampus correlated positively with the PIQ score (n = 7, R2 = 0.6662, p = 0.0251).
We are not sure about the significance of this finding, as it was unexpected. It is possible
that this result within the healthy hippocampus may result from our small sample size.
Conversely, increases in glutamate within physiologic ranges in the non-epileptogenic
hippocampus may represent cognitive activation, which correlates with improved
performance on the PIQ. For this reason, further investigation may beneficial to clarify
this finding. Based on these data demonstrating little statistical significance between
right and left hippocampal probes within both epileptogenic and non-epileptogenic
probes, laterality effects will not be included during further analysis in this study.
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Given evidence that elevated glutamate levels can be neurotoxic (7-9) and are
associated with hippocampal neuronal loss and volume reduction (Cavus, unpublished
data), and that these hippocampal pathologies are associated with verbal memory
impairment (42-49), we sought to investigate whether elevated baseline glutamate levels
in the epileptogenic hippocampus are associated with poorer cognitive function as
compared to the non-epileptogenic hippocampus. The extracellular glutamate levels in
the epileptogenic hippocampus correlated inversely with neuropsychological
performance scores only on the V-SRT (R2 = 0.36, p = 0.0244) (see Figure 5), but not for
other tests (VIQ, PIQ, FSIQ, VM-SRT) (p > 0.05, linear regression model). This result is
consistent with our hypothesis; an increase in basal glutamate levels to abnormally high
levels is correlated with impaired hippocampal functioning measured by lower scores on
the V-SRT, which is a test specific for hippocampal function. However, elevated basal
glutamate levels in the epileptogenic hippocampus do not correlate with decreased scores
on other neuropsychological assessments (VIQ, PIQ, FSIQ, and VM-SRT), which are
less specific measures of hippocampal function. In the non-epileptogenic hippocampus
where basal glutamate levels lie within normal ranges, there were no significant
correlations between extracellular glutamate levels and neuropsychological performance
scores for any measure (VIQ, PIQ, FSIQ, V-SRT, VM-SRT) (p > 0.05 for all
correlations). This finding is consistent with our hypothesis given that physiologic levels
of extracellular glutamate are not expected to impair cognitive processing, therefore
further analysis within this study will be confined to the epileptogenic probes.
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Figure 5. The relationship between basal extracellular glutamate levels in the
epileptogenic hippocampus and V-SRT scores.
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Basal glutamate levels and performance scores on the V-SRT are significantly and
inversely correlated within the epileptogenic hippocampus, where the extracellular
glutamate levels are abnormally high. Log transformation data were plotted according
to the linear regression model. (* p < 0.05)

Thus far, our analysis of the relationship between basal glutamate levels and
cognitive function has included all epileptogenic probes. In light of evidence suggesting
that MRI-detected hippocampal atrophy is associated with decreased performance on
neuropsychological assessment of verbal memory (47-49), we sought to clarify the
relationship between glutamate levels and cognitive function among epileptogenic probes
by controlling for the presence or absence of hippocampal atrophy. Of the 14
epileptogenic probes, 6 were located in atrophic hippocampus and 8 in non-atrophic
hippocampus (Table 1). Within the epileptogenic probes, the basal glutamate level (mean
± SD) in atrophic hippocampus (18.36 ± 16.30µM, n = 6) is much greater than in nonatrophic hippocampus (7.15 ± 5.19µM, n = 8). However, this difference did not reach
statistical significance (p > 0.05, t-test on log-transformed data), which is likely the result
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of our small sample size (see Figure 6). Within the non-epileptogenic probes, the basal
glutamate level (mean ± SD) from non-atrophic hippocampus was 2.92 ± 1.46µM (n = 8).
Only one probe was located in the atrophic hippocampus, thus precluding further analysis
within this group.

Fig 6. Basal extracellular glutamate levels in the atrophic and non-atrophic
epileptogenic hippocampus.
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Within epileptogenic hippocampus, basal glutamate levels in atrophic hippocampus were
much higher than in non-atrophic hippocampus. However this difference did not reach
statistical significance (p > 0.05), likely due to small sample size.

Further analysis was conducted to examine the effect of atrophy on the
relationship between basal glutamate levels and individual neuropsychological
assessment scores (VIQ, PIQ, FSIQ, V-SRT, and VM-SRT) within epileptogenic probes.
Analysis of co-variance (ANCOVA) test was utilized with atrophy as a co-variant, basal
glutamate levels as predictor, and neuropsychological test results as outcome, followed
by linear regression analysis. The relationship between glutamate levels and V-SRT

35
scores has been demonstrated to be significant within all epileptogenic probes; however
when controlling for the presence of atrophy on ANCOVA tests it is revealed that this
relationship is significant only within atrophic hippocampus (F(1,5) = 13.89, p = 0.0204),
but not within non-atrophic hippocampus (F(1,7) = 0.68, p = 0.4424) (see Figure 7, A-B).
In addition, although glutamate levels did not correlate significantly with the PIQ scores
in the epileptogenic hippocampus, when controlled for the presence of atrophy, the
glutamate levels correlated inversely with the PIQ scores within atrophic hippocampus
(R2 = 0.7324, p = 0.0297), but not within non-atrophic hippocampus (R2 = 0.2303, p =
0.2288) (see Fig 7, C-D). These results indicate that within atrophic hippocampus,
elevated basal glutamate levels are associated with significantly decreased cognitive
performance as measured by both the V-SRT and PIQ tests. There were no significant
interactions with atrophy as a co-variant for any of the other neuropsychological
measures (VIQ, FSIQ, and VM-SRT, p > 0.05).
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Figure 7, A-D. The relationship between basal extracellular glutamate levels in the
atrophic and non-atrophic epileptogenic hippocampus and performance scores on
V-SRT and PIQ tests.
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Within epileptogenic hippocampus, the increase in the basal glutamate level in the
atrophic hippocampus, but not the non-atrophic hippocampus, correlated significantly
with lower performance on the V-SRT test (A and B) and on the PIQ test (C and D). Log
transformed glutamate data is plotted against the cognitive task scores according to
linear regression model. (* p < 0.05)
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Discussion
This study explores the relationship between the extracellular glutamate level in
the hippocampus and the cognitive performance of patients with medication-resistant
localization-related epilepsies. We used the zero-flow microdialysis method to estimate
the basal extracellular concentration of glutamate in the epileptogenic and nonepileptogenic hippocampus of conscious neurosurgical epileptic patients during the
interictal period (Table 1). The epileptogenic hippocampus had high basal glutamate
levels (mean, 11.96µM; in some cases exceeding 35µM) which far exceeds neurotoxic
glutamate levels of 5 micromolar or greater (82-84). In contrast, the non-epileptogenic
hippocampus maintained low glutamate levels (mean, 2.92µM), which were within the
range of previous studies in humans (69) and animals (85). We argue that the elevated
basal glutamate levels in the epileptogenic hippocampus may be responsible for impaired
cognitive functioning in patients with temporal lobe epilepsy.
Previous studies have reported that elevated glutamate levels are associated with
cell loss and hippocampal atrophy in animals (86-88) and humans (Cavus, unpublished
data), and that both cell loss and hippocampal atrophy are associated with verbal memory
impairment (42-49). Our data demonstrate that elevated basal glutamate levels are
associated with decreased performance on certain hippocampal cognitive tests.
Specifically, elevated basal glutamate levels in the epileptogenic hippocampus are
correlated with impaired verbal memory measured by the V-SRT, which is a
neuropsychological assessment tool specific for hippocampal verbal functioning (44) (see
Figure 5). Furthermore, when controlling for the presence or absence of MRI-detected
hippocampal atrophy within epileptogenic regions, our study reveals that elevated basal
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glutamate levels within atrophic hippocampus are correlated with decreased cognitive
functioning measured by both the V-SRT and PIQ tests, but not within non-atrophic
hippocampus (see Figure 7, A-D). No associations were elucidated between elevated
basal glutamate levels in both atrophic and non-atrophic epileptogenic hippocampus and
impaired cognitive performance measured by the VIQ, FSIQ, and VM-SRT. In the nonepileptogenic hippocampus, no associations were found between glutamate levels and
performance on neuropsychological tests in agreement with our hypothesis. Basal
glutamate levels remained low within this group, suggesting that the synaptic release and
reuptake of glutamate is predominantly intact. Thus, it is reasonable to suggest that the
activity-dependent synaptically-released glutamate is contained mostly within the
synaptic cleft, and the low levels of extrasynaptic glutamate do not interfere with the
glutamatergic signal processing that mediates cognitive functions (6).
Our data correlating elevated basal glutamate levels with impaired cognition do
not imply causation. However, they are consistent with our proposed mechanism of
neuropathology in which neurotoxic levels of glutamate damage the hippocampus and
consequently impair cognitive functioning. Within epileptogenic hippocampus,
glutamate concentrations may rise to neurotoxic levels as a result of impaired reuptake,
excess synthesis and release, or impaired glutamate-glutamine cycling (69). Excessive
concentrations of glutamate are known to produce excitotoxic cell death (7, 9), which
may impair cellular functioning at the synaptic level, as well as mediate hippocampal cell
loss and MRI-detected pathology (46, 47). We found that within epileptogenic probes,
correlations existed between elevated glutamate levels and decreased cognitive
processing for the atrophic hippocampus, but not for the non-atrophic hippocampus (see
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Figure 7, A-D). This suggests that atrophy alone is not sufficient for impaired cognitive
processing, but may require the concomitant elevation of glutamate concentrations. We
therefore propose that the aforementioned cognitive deficits occur as a result of elevated
glutamate levels with resultant neurotoxicity, and not simply from the presence of
hippocampal cell loss and atrophy.
The association between elevated basal glutamate levels in the epileptogenic
atrophic hippocampus and decreased scores on the V-SRT is consistent with our
hypothesis, as this measure has been previously demonstrated to be specific for
pyramidal cell loss (44). However, the association between elevated glutamate and
decreased performance on the PIQ was unexpected, as this test is a measure of overall
intelligence which depends primarily upon global cognitive processes (41), and is not
sensitive for hippocampal pathology (42). This finding may be spurious given our small
sample size (n = 6). Alternately, although PIQ measures nonverbally-mediated global
cortical function (42), the subtests of block design and object assembly measure aspects
of visual-spatial ability, to which the hippocampus is believed to contribute. Numerous
studies have demonstrated hippocampal involvement in the encoding and retrieval of
visual-spatial memory in animals (24, 89-91). For example, rodents with specific lesions
of the hippocampal formation demonstrate impairments in navigating to a goal location
(89-91). Defining the hippocampal role in visual-spatial memory within humans has
been more complicated, since the method of memorizing a spatial location to reach a goal
has been unique to rodent models (92). However, in a recent functional magnetic
resonance imaging (fMRI) study in humans, Astur and colleagues (92) demonstrated
hippocampal activation occurs during the performance of a computer-generated virtual
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reality 8-arm radial maze, thus mimicking the design of rodent studies. Furthermore, the
hippocampus has been implicated in other non-verbally mediated cognitive tasks in
human fMRI studies, including face recognition (93) and picture recognition (94). Given
the role of the hippocampus in visual-spatial memory processing, elevated glutamate
levels within the atrophic epileptogenic hippocampus may result in neuronal damage and
subsequent impairment in visual-spatial learning, as detected by the PIQ. However,
further studies will be necessary to clarify the significance of this finding.
No associations were found between glutamate levels and cognitive performance
on measures of VIQ and FSIQ; this is consistent with our hypothesis given the V-SRT is
more dependent upon hippocampal function than the VIQ (44), and the FSIQ is a
composite score to which the VIQ contributes (41). The VM-SRT measures visualspatial memory which is believed to be a non-dominant (usually right) hippocampaldependent task (41), however our results are not entirely consistent with this, as elevated
glutamate levels do not impair function on this test. We would expect that epileptogenic,
right-sided, atrophic hippocampus would have elevated basal glutamate levels which
might correlate with impaired VM-SRT performance. However, only 3 patients within
this study fulfill these criteria (Table 1); this small patient sample size may preclude
emergence of statistical significance, therefore future studies are warranted.
Our study sample consists of patients who are left hemisphere dominant for
language as measured by the intracarotid amobarbital procedure. As the dominant
hippocampus has been implicated in verbal memory and the non-dominant hippocampus
with visual-spatial learning (17), we would expect elevated glutamate levels in the leftsided epileptogenic hippocampus to be associated with decreased performance on the V-
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SRT, and the right-sided epileptogenic hippocampus with impaired visual-spatial testing.
However, our results do not demonstrate significant effects regarding laterality. Of note,
in the right (non-dominant) hemisphere, associations between glutamate levels and VIQ,
PIQ, and FSIQ scores were bordering significance. In addition, within healthy left-sided
hippocampus where glutamate levels are maintained at physiologic levels, a significant
correlation exists between glutamate levels and PIQ scores. These data may be spurious
given our small sample size, however the effects of laterality would benefit further
investigation in studies involving more subjects.
Our study was confined to probes located in the anterior hippocampus, as mesial
temporal lobe epilepsy preferentially involves the anterior mesial lobe and intraoperative
probe placement was determined by clinical suspicion of seizure focus. Prior studies
have reported differential involvement of the anterior and posterior hippocampus in
cognitive processing (24, 26), such that the anterior hippocampus is believed to be
involved in memory encoding of novel stimuli, while the posterior hippocampus is
believed to mediate memory retrieval, familiar information processing, and verbal and
spatial memory (25, 27-32). In light of these prior studies, we would not expect to see a
robust correlation between glutamate levels in the anterior hippocampus and verbal
memory tests. However, we noted a significant correlation (R2 = 0.7764, p = 0.0204)
between elevated glutamate concentrations in the epileptogenic atrophic hippocampus
and verbal memory measured by the V-SRT. This suggests that verbal information
processing is not confined to the posterior hippocampus, but may also involve anterior
regions. In addition, the heterogeneous function of the hippocampus along its anteriorposterior axis predicts that little visual-spatial cognitive activity would occur in the
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anterior hippocampus. This may contribute to our data demonstrating no significant
correlation between glutamate levels in the anterior epileptic atrophic hippocampus and
visual-spatial activity measured by the VM-SRT. Furthermore, our small sample size has
precluded examination of both anterior and posterior hippocampus, thus the selective
effects of glutamate levels within the anterior versus posterior hippocampus on cognitive
functioning would benefit further study employing a larger sample size.

Confounding Factors
There are several limitations to the present study. First, the technique of
intracerebral microdialysis was used to estimate extracellular glutamate concentrations in
the conscious human hippocampus. It is important to note that microdialysis sampling
reflects a pooled measure of extracellular fluid in the immediate vicinity of the catheter,
which may differ considerably from intra-synaptic concentrations of neurotransmitters.
The small sampling tissue volume of the microdialysis may not reflect the overall
chemical milieu in the hippocampus, where larger regions may be involved in a given
cognitive task. Nonetheless, microdialysis provides the closest in vivo look at
neurobiological activity at the extracellular space in the awake human brain and permits
the investigation of cognition at the level of neurotransmitters. Second, because the
investigational procedure employed in this study involves an invasive intracranial
surgical procedure within a specific subset of patients with medically refractory epilepsy,
there is a paucity of patients available for study, even in a large epilepsy center over the
course of 5 years. The small patient size examined in this investigation may have
prevented the emergence of statistically significant results that would have been realized
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in a larger study, and may have resulted in spurious results that would not be significant
within a greater sample size. Finally, this study is designed to examine the relationship
between glutamate levels in epileptogenic and non-epileptogenic hippocampus and
cognitive function measured by neuropsychological tests. It would be presumably very
difficult to control for the possible patient who has an intracranial probe in nonepileptogenic (and presumably healthy) hippocampus, but has an additional vigorously
epileptogenic hippocampal seizure focus not captured by probe sampling and which may
impair cognitive function, thus generating inaccurate correlations.

Clinical Implications
Within neuropsychiatry, there exists an abundance of clinical disorders associated
with hippocampal structural abnormalities. As reviewed by Astur and colleagues (92),
patients with schizophrenia and post-traumatic stress disorder often have smaller
hippocampus than aged-matched controls, while patients with Alzheimer’s disease may
experience the earliest signs of neurodegeneration within the hippocampus followed by
subsequent development of amyloid plaques and neurofibrillary tangles. Mesial temporal
lobe epilepsy patients suffer most commonly from mesial temporal sclerosis,
characterized by hippocampal atrophy and gliosis (51, 52). Given the pivotal role of the
hippocampus in learning and memory, these disorders occur concomitantly with deficits
in cognitive functioning. The present study demonstrates the association between
elevated glutamate levels and impairment of certain forms of cognitive functioning in the
setting of hippocampal atrophy. The abnormally enhanced glutamatergic activity may
result in excitotoxic cell damage and death to hippocampal structures, thus serving as a
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possible mechanism of neuropathological injury and subsequent cognitive impairment.
Meaningful clinical implications may therefore exist for potential treatment options of
diseases mediated by glutamate neurotoxicity and subsequent hippocampal atrophy.
Specifically, lowering the basal extracellular glutamate with medications may help to
alleviate neuronal cell loss and sclerosis and preserve cognitive functioning. In
agreement, glutamate-receptor antagonists have been shown to possess both
anticonvulsant and neuroprotective properties (70).
To our knowledge, this is the first study to demonstrate the association between
basal glutamate levels in conscious humans undergoing microdialysis and baseline
neuropsychological functioning. However, as our sample size was small (n = 22), future
investigation is warranted to clarify points where our data revealed borderline statistical
significance (i.e., glutamate levels in the right epileptogenic hippocampus versus PIQ,
VIQ, and FSIQ), lack of significance where meaningful relationships were expected
conceptually (i.e., glutamate levels in the right epileptogenic hippocampus versus VMSRT), and statistical significance where it was not initially hypothesized (i.e., glutamate
levels in the epileptogenic atrophic hippocampus versus PIQ). Although effects of
laterality are not demonstrated in the present report, this finding is likely the result of our
small sample size and would benefit further investigation in a larger study. Furthermore,
additional study exploring glutamate levels within both the anterior and the posterior
hippocampus would be helpful to elucidate the function of the hippocampus along its
longitudinal axis, as compared to neuropsychological measures.
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Conclusion
In summary, glutamate is the principal excitatory neurotransmitter and levels
remain low in healthy brain, however concentrations may rise to neurotoxic levels in the
epileptogenic hippocampus (1, 5, 7, 64-70). The hippocampus is responsible for learning
and memory (15-17, 24-27), thus impaired hippocampal function in TLE is associated
with cognitive deficits (40, 54, 55). Specifically, microdialysis evidence demonstrates
that elevated glutamate levels are associated with cell loss and hippocampal atrophy
(Cavus, unpublished data), and previous studies have demonstrated that both cell loss and
hippocampal atrophy are associated with verbal memory impairment (42-49). Our data
demonstrate that basal glutamate concentrations within the epileptogenic hippocampus
reach neurotoxic levels and are significantly higher than the non-epileptogenic
hippocampus. Elevated basal glutamate levels in the epileptogenic hippocampus are
associated with decreased verbal memory performance measured by the V-SRT. When
controlling for atrophy, elevated basal glutamate levels in the epileptogenic hippocampus
are associated with impairment on V-SRT and PIQ performance, but not in epileptogenic
non-atrophic hippocampus. We propose that the aforementioned cognitive deficits occur
as a result of elevated glutamate levels with resultant neurotoxicity and subsequent
hippocampal pathology. This mechanism of injury may occur in epilepsy and other
clinical disorders marked by hippocampal pathology such as schizophrenia, posttraumatic stress disorder, and Alzheimer’s disease. This provides the opportunity for
treatment options aimed to medically maintain intrahippocampal glutamate at low levels
to prevent neurotoxicity, which may in turn help patients preserve their cognitive
function.
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